Alzheimer’s Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: Among the neurodegenerative diseases of aging, sporadic Alzheimer’s disease (AD) is the most prevalent and perhaps the most feared. With virtually no success at finding pharmaceutical therapeutics for altering progressive AD after diagnosis, research attention is increasingly directed at discovering biological and other markers that detect AD risk in the long asymptomatic phase. Both early detection and precision preclinical intervention require systematic investigation of multiple modalities and combinations of AD-related biomarkers and risk factors. We extend recent unbiased metabolomics research that produced a set of metabolite biomarker panels tailored to the discrimination of cognitively normal, cognitively impaired and AD patients. Specifically, we compare the prediction importance of these panels with five other sets of modifiable and non-modifiable AD risk factors (genetic, lifestyle, cognitive, functional health, and bio-demographic) in three clinical groups. Method: The three groups were: Cognitively Normal (CN; n = 35), Mild Cognitive Impairment (MCI; n = 25), and AD (n = 22). In a series of three pairwise comparisons, we used machine learning technology (Random Forest Analysis, RFA) to test relative predictive importance of up to 19 risk biomarkers from the six AD risk domains. Results: The three RFA multimodal prediction analyses produced significant discriminating risk factors. First, discriminating AD from CN was the AD metabolite panel and two cognitive markers. Second, discriminating AD from MCI was the AD/MCI metabolite panel and two cognitive markers. Third, discriminating MCI from CN was the MCI metabolite panel and seven markers from four other risk modalities: genetic, lifestyle, cognition, and functional health. Conclusions: Salivary metabolomics biomarker panels, supplemented by other risk markers, were robust predictors of (1) clinical differences in impairment and dementia and even (2) subtle differences between CN and MCI. For the latter, the metabolite panel was supplemented by biomarkers that were both modifiable (e.g., functional) and non-modifiable (e.g., genetic). Comparing, integrating, and identifying important multi-modal predictors may lead to novel combinations of complex risk profiles potentially indicative of neuropathological changes in asymptomatic or preclinical AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
MissForest—Non-parametric missing value imputation for mixed-type data
Stekhoven, D. J., & Bühlmann, P. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr597 · Cited by 6,156
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 2×
“Education has widely been used as a proxy for cognitive reserve (Tucker and Stern, 2011; Stern, 2012, 2017).”
BackgroundMethodHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“All four were detected in genome-wide association studies and frequently linked to AD and cognitive decline (Harold et al., 2009; Lambert et al., 2009; Chibnik et al., 2011).”
Strobl, C., Malley, J., & Tutz, G. (2009) · Psychological Methods · doi:10.1037/a0016973 · Cited by 2,583
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Given the lack of success in developing therapeutics to reverse the course of neurodegeneration in aging after diagnosis (Cummings et al., 2014), research and clinical attention has shifted to multimodal risk detection in asymptomatic phases (Sperling et al.”
BackgroundMild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
The stroop color and word test
Scarpina, F., & Tagini, S. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.00557 · Cited by 1,661
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
The worldwide costs of dementia 2015 and comparisons with 2010
Wimo, A., Guerchet, M., Ali, G., Wu, Y., Prina, A. M., Winblad, B., Jönsson, L., Liu, Z., & Prince, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.150 · Cited by 1,066
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025 · cited 2×
“…pressure alone (Raz et al., 2011; Nation et al., 2013) and linked to (1) AD biomarkers in CN and AD risk (Nation et al., 2013; McFall et al., 2016); (2) MCI (Yaneva-Sirakova et al., 2012); (3) cerebral small vessel disease (Singer et al., 2014); and (4) cognitive decline (McFall et al., 2015b).”
BackgroundUse it or lose it: Engaged lifestyle as a buffer of cognitive decline in aging?
Hultsch, D. F., Hertzog, C., Small, B. J., & Dixon, R. A. (1999) · Psychology and Aging · doi:10.1037/0882-7974.14.2.245 · Cited by 1,023
Self-citationBherer, L., Erickson, K. I., & Liu-Ambrose, T. (2013) · Journal of Aging Research · doi:10.1155/2013/657508 · Cited by 899 · cited 1×
“A standard self-report instrument represented levels of everyday integrative cognitive, novel cognitive, physical and social activities (Deary et al., 2006; Bherer et al., 2013; Wang et al., 2013; Vemuri et al., 2014; Thibeau et al., 2017).”
BackgroundSex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Bondi, M. W., Initiative, F. T. A. D. N., Edmonds, E. C., Jak, A. J., Clark, L. R., Delano-Wood, L., McDonald, C. R., Nation, D. A., Libon, D. J., Au, R., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140276 · Cited by 772 · cited 1×
“Overall, this approach emphasizes objective and stable classification, reducing the risk of false assignments and enhancing homogeneity of the groups (Dolcos et al., 2012; Bondi et al., 2014; Dixon et al., 2014).”
MethodCognitive impairment in preclinical Alzheimer's disease: a meta-analysis
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005) · Neuropsychology · doi:10.1037/0894-4105.19.4.520 · Cited by 735
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
M. Tucker, A., & Stern, Y. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745320 · Cited by 561 · cited 1×
“Education has widely been used as a proxy for cognitive reserve (Tucker and Stern, 2011; Stern, 2012, 2017).”
MethodSex differences in cognitive impairment and Alzheimer’s disease
Li, R., & Singh, M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.002 · Cited by 527
Brain abnormalities in human obesity: A voxel-based morphometric study
Pannacciulli, N., Del Parigi, A., Chen, K., Le, D. S. N. T., Reiman, E. M., & Tataranni, P. A. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.047 · Cited by 523
Turken, U., Whitfield-Gabrieli, S., Bammer, R., Baldo, J. V., Dronkers, N. F., & Gabrieli, J. D. E. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.057 · Cited by 500
Identifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · cited 1×
“…other standard AD biomarkers, such as cerebrospinal fluid β-amyloid (1–42), Frontiers in Aging Neuroscience | www.frontiersin.org 8 October 2018 | Volume 10 | Article 296 total tau, and phospho-tau-181 (Humpel, 2011), as well as other AD-specific neuroimaging biomarkers (e.g., hippocampal volume).”
BackgroundThe age factor in Alzheimer’s disease
Guerreiro, R., & Bras, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0232-5 · Cited by 415
High total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Leisure activities and the risk of amnestic mild cognitive impairment in the elderly
Verghese, J., LeValley, A., Derby, C., Kuslansky, G., Katz, M., Hall, C., Buschke, H., & Lipton, R. B. (2006) · Neurology · doi:10.1212/01.wnl.0000202520.68987.48 · Cited by 373
Koepsell, T. D., & Monsell, S. E. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e26b7 · Cited by 369
Sex differences in Alzheimer's disease and other dementias
Mazure, C. M., & Swendsen, J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00067-3 · Cited by 350 · cited 2×
“Sex differences have been observed in AD with significantly higher prevalence in women than men (Mazure and Swendsen, 2016).”
BackgroundLate Life Leisure Activities and Risk of Cognitive Decline
Wang, H.-X., Jin, Y., Hendrie, H. C., Liang, C., Yang, L., Cheng, Y., Unverzagt, F. W., Ma, F., Hall, K. S., Murrell, J. R., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls153 · Cited by 239
MyCompoundID: using an evidence-based metabolome library for metabolite identification
Li, L., Li, R., Zhou, J., Zuniga, A., Stanislaus, A. E., Wu, Y., Huan, T., Zheng, J., Shi, Y., Wishart, D. S., et al. (2013) · Analytical Chemistry · doi:10.1021/ac400099b · Cited by 229 · cited 2×
“In addition, putative metabolite identification was performed based on accuratemassmatch of the peak pairs found to themetabolites in the Human Metabolome Database (Wishart et al., 2013) and the Evidence-based Metabolome Library using MyCompoundID (Li et al., 2013), with a mass tolerance of 5 ppm.”
MethodSelf-citationMetabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases
Jové, M., Portero-Otín, M., Naudí, A., Ferrer, I., & Pamplona, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000091 · Cited by 195
Xiao, Q., Gil, S.-C., Yan, P., Wang, Y., Han, S., Gonzales, E., Perez, R., Cirrito, J. R., & Lee, J.-M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338376 · Cited by 194 · cited 1×
“Potential mechanisms (Emmerzaal et al., 2015) include: (1) greater inflammation (Yaffe et al., 2004); (2) structural brain changes (Pannacciulli et al., 2006); and (3) higher cholesterol levels in mid-life and lower levels in late-life (Mielke et al., 2005).”
BackgroundEffect of lifestyle activities on alzheimer disease biomarkers and cognition
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Roberts, R. O., Lowe, V. J., Kantarci, K., Senjem, M. L., Gunter, J. L., Boeve, B. F., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23665 · Cited by 193
Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible
Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182
CR1 is associated with amyloid plaque burden and age‐related cognitive decline
Chibnik, L. B., Shulman, J. M., Leurgans, S. E., Schneider, J. A., Wilson, R. S., Tran, D., Aubin, C., Buchman, A. S., Heward, C. B., Myers, A. J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22277 · Cited by 174
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147 · cited 1×
“Arguably, identifying perturbations in profiles of biomarkers in asymptomatic periods of impairment or AD may provide a promising opportunity for developing precision or programmatic interventions that could delay or prevent clinical diagnosis (Imtiaz et al., 2014; Hampel et al., 2017).”
BackgroundGauthier, S., Patterson, C., Chertkow, H., Gordon, M., Herrmann, N., Rockwood, K., Rosa-Neto, P., & Soucy, J.-P. (2012) · Canadian Geriatrics Journal · doi:10.5770/cgj.15.49 · Cited by 137
Complement receptor 1 (CR1) and Alzheimer's disease
Crehan, H., Holton, P., Wray, S., Pocock, J., Guerreiro, R., & Hardy, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.017 · Cited by 129
Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., Clarke, E. V., Rogers, J., Atkinson, J. P., & Tenner, A. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149792 · Cited by 87
Brown, C. L., Robitaille, A., Zelinski, E. M., Dixon, R. A., Hofer, S. M., & Piccinin, A. M. (2016) · Psychology and Aging · doi:10.1037/pag0000134 · Cited by 73 · cited 1×
“Social activity (n = 7) included volunteering or visiting friends (Brown et al., 2016).”
BackgroundSelf-citation
Cited by
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Self-citationGarcía-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Anstey, K. J., Peters, R., Zheng, L., Barnes, D. E., Brayne, C., Brodaty, H., Chalmers, J., Clare, L., Dixon, R. A., Dodge, H., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200674 · Cited by 40
“Similarly, data from observational studies could be used to evaluate interactions or joint effects of risk factor combinations [31].”
MethodSelf-citation
Metadata
- Authors
- Sapkota, S., Huan, T., Tran, T., Zheng, J., Camicioli, R., Li, L., & Dixon, R. A.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-10-02
- Volume
- 10
- Pages
- 296-296
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2894884164
- Cited by
- 35
- References
- 40
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.